10559675 03/01/2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  3  NOV 26  MARPAT enhanced with FSORT command
 NEWS  4  NOV 26  CHEMSAFE now available on STN Easy
 NEWS  5  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS  6  DEC 01  ChemPort single article sales feature unavailable
 NEWS  7  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS  8  DEC 17  Fifty-one pharmaceutical ingredients added to PS
 NEWS  9  JAN 06  The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10  JAN 07  WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                  Classification Data
 NEWS 11  FEB 02  Simultaneous left and right truncation (SLART) added
                  for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
 NEWS 12  FEB 02  GENBANK enhanced with SET PLURALS and SET SPELLING
 NEWS 13  FEB 06  Patent sequence location (PSL) data added to USGENE
 NEWS 14  FEB 10  COMPENDEX reloaded and enhanced
 NEWS 15  FEB 11  WTEXTILES reloaded and enhanced
 NEWS 16  FEB 19  New patent-examiner citations in 300,000 CA/CAplus
                  patent records provide insights into related prior
                  art
 NEWS 17  FEB 19  Increase the precision of your patent queries -- use
                  terms from the IPC Thesaurus, Version 2009.01
 NEWS 18  FEB 23  Several formats for image display and print options
                  discontinued in USPATFULL and USPAT2
 NEWS 19  FEB 23  MEDLINE now offers more precise author group fields
                  and 2009 MeSH terms
 NEWS 20  FEB 23  TOXCENTER updates mirror those of MEDLINE - more
                  precise author group fields and 2009 MeSH terms
 NEWS 21  FEB 23  Three million new patent records blast AEROSPACE into
                  STN patent clusters
 NEWS 22  FEB 25  USGENE enhanced with patent family and legal status
                  display data from INPADOCDB
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
```

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:43:23 ON 01 MAR 2009

=> FILE REG
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 19:43:32 ON 01 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 FEB 2009  HIGHEST RN 1113101-98-6
DICTIONARY FILE UPDATES:  27 FEB 2009  HIGHEST RN 1113101-98-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10559675.str
```





chain nodes :
9 10 11 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
3-9 9-10 10-11 11-12 11-14 12-13 13-15
ring bonds :
1-2 1-5 1-8 2-3 3-4 4-5 5-6 6-7 7-8
exact/norm bonds :
1-2 1-5 1-8 2-3 3-4 4-5 5-6 6-7 7-8 9-10 10-11 11-12 11-14 12-13
13-15
exact bonds :
3-9

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> S L1
SAMPLE SEARCH INITIATED 19:44:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\105596753.str
```



```
chain nodes :
9  10  11  12
ring nodes :
1  2  3  4  5  6  7  8
chain bonds :
3-9  9-10  10-11  11-12
ring bonds :
1-2  1-5  1-8  2-3  3-4  4-5  5-6  6-7  7-8
exact/norm bonds :
1-2  1-5  1-8  2-3  3-4  4-5  5-6  6-7  7-8  9-10  10-11  11-12
exact bonds :
3-9


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:CLASS  10:CLASS
11:CLASS  12:CLASS




L3      STRUCTURE UPLOADED

=> D
L3 HAS NO ANSWERS
L3              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> S L3
SAMPLE SEARCH INITIATED 19:45:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       18 TO ITERATE

100.0% PROCESSED       18 ITERATIONS                              5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          106 TO      614
PROJECTED ANSWERS:               5 TO      234

L4            5 SEA SSS SAM L3

=> S L3 FULL
FULL SEARCH INITIATED 19:45:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      320 TO ITERATE

100.0% PROCESSED      320 ITERATIONS                             42 ANSWERS
SEARCH TIME: 00.00.01

L5           42 SEA SSS FUL L3

=> FILE CAPLUS
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 187.32     187.54

FILE 'CAPLUS' ENTERED AT 19:45:49 ON 01 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Mar 2009 VOL 150 ISS 10
FILE LAST UPDATED: 27 Feb 2009 (20090227/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> S L5
L6   2 L5

=> D IBIB ABS HISTR TOT
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

```
HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D IBIB ABS HISTR TOT
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
```

```
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D L5  IBIB ABS HITSTR TOT
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:N


=> D L6 IBIB ABS HISTR TOT
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
```

```
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D L6 IBIB ABS HITSTR TOT
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1127390 CAPLUS
DOCUMENT NUMBER: 142:74577
TITLE: Preparation of imidazothiadiazolesulfonamides for treatment of neuronal disorders and proliferative disease.
INVENTOR(S): Jaquith, James B.; Gillard, John W.
PATENT ASSIGNEE(S): Aegera Therapeutics Inc., Can.
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111061	A1	20041223	WO 2004-CA873	20040614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2527906	A1	20041223	CA 2004-2527906	20040614
EP 1636242	A1	20060322	EP 2004-737814	20040614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1835956	A	20060920	CN 2004-80023222	20040614
JP 2006527209	T	20061130	JP 2006-515592	20040614
US 20070112043	A1	20070517	US 2005-559675	20051206
IN 2005KN02571	A	20070706	IN 2005-KN2571	20051212

PRIORITY APPLN. INFO.: US 2003-477967P P 20030613
WO 2004-CA873 W 20040614

OTHER SOURCE(S): MARPAT 142:74577
GI



I

AB Title compds. [I; R1 = COR9, CO(CH2)n(CO)p(OCH2CH2)mOR10,

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CO(CHR11)qNR12R13; R2 = H; R5 = H, Me, (substituted) PhCH2; R6 = fluoroalkyl, (substituted) aryl, heteroaryl, biphenyl, di-Ph ether, coumarinyl, adamantyl, etc.; R9 = (substituted) alkyl, aryl; R10 = H, (substituted) alkyl, aryl, heteroaryl; R11 = H, (substituted) alkyl, aralkyl, aryl, heteroaryl; R12, R13 = H, (substituted) alkyl, aralkyl, aryl, heteroaryl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl; R12R13 = atoms to form a 5-7 membered (substituted) heterocyclyl; n = 0-6; p = 0, 1; m = 0-22; q = 1-5], were prepd. Thus, I (R1, R2, R5 = H; R6 = Ph) was stirred with AcCl and Et3N in THF for 16 h to give 95% I (R1 = Ac; R2, R5 = H; R6 = Ph). The latter showed soly. of 10 mg/mL in PBS/HPCD. I were active in reducing loss of sensory nerve conduction velocity in rats treated with cisplatin.
IT 1026675-12-6 1026723-06-7
RL: PRPH (Prophetic)
(Preparation of imidazothiadiazolesulfonamides for treatment of neuronal disorders and proliferative disease.)
RN 1026675-12-6 CAPLUS
CN Butanamide, N-[[6-(3'-methoxy[1,1'-biphenyl]-4-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 1026723-06-7 CAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]- (CA INDEX NAME)



IT 812696-94-9P 812696-95-0P 812696-96-1P
812696-97-2P 812696-99-4P 812697-00-0P
812697-03-3P 812697-05-5P 812697-07-7P
812697-08-8P 812697-09-9P 812697-10-2P
812697-11-3P 812697-12-4P 812697-13-5P
812697-14-6P 812697-15-7P 812697-16-8P
812697-17-9P 812697-18-0P 812697-19-1P
812697-20-4P 812697-21-5P 812697-22-6P
812697-23-7P 812697-24-8P 812697-25-9P
812697-26-0P 812697-27-1P 812697-37-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Uses)
(prepn. of imidazothiadiazolesulfonamides for treatment of neuronal disorders and proliferative diseases)
RN 812696-94-9 CAPLUS
CN Acetamide, N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]- (CA INDEX NAME)



RN 812696-95-0 CAPLUS
CN Butanamide, N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]- (CA INDEX NAME)



RN 812696-96-1 CAPLUS
CN Carbamic acid, [(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 812696-97-2 CAPLUS
CN Carbamic acid, [2-oxo-2-[[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 812696-99-4 CAPLUS
CN Acetamide, 2-amino-N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CM 1

CRN 812696-98-3
CMF C12 H11 N5 O3 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 812697-00-0 CAPLUS
CN Butanoic acid, 4-oxo-4-[[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]amino]- (CA INDEX NAME)



RN 812697-03-3 CAPLUS
CN Carbamic acid, [(1S)-3-(methylthio)-1-[[[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]amino]carbonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-05-5 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 812697-04-4
CMF C15 H17 N5 O3 S3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 812697-07-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 812697-06-6

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CMF C15 H15 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 812697-08-8 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[6-(4-fluorophenyl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-09-9 CAPLUS
CN Acetamide, N-[[6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-10-2 CAPLUS
CN Acetamide, N-[[6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-2-methoxy- (CA INDEX NAME)

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-11-3 CAPLUS
CN Butanamide, N-[[6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-12-4 CAPLUS
CN Butanamide,
N-[[6-[4-(4-morpholinyl)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-13-5 CAPLUS
CN Acetamide, N-[[6-(3'-methoxy[1,1'-biphenyl]-4-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-14-6 CAPLUS
CN Acetamide,
2-methoxy-N-[[6-(3'-methoxy[1,1'-biphenyl]-4-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-15-7 CAPLUS
CN Acetamide,
N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-16-8 CAPLUS
CN Butanamide,
N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-17-9 CAPLUS
CN Acetamide,
2-(2-methoxyethoxy)-N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-18-0 CAPLUS
CN Acetamide,
2-[2-(2-methoxyethoxy)ethoxy]-N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 812697-19-1 CAPLUS
CN Carbamic acid, [[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 812697-20-4 CAPLUS
CN Acetamide, N-[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-21-5 CAPLUS
CN Acetamide, N-[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-2-methoxy- (CA INDEX NAME)

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-26-0 CAPLUS
CN Carbamic acid, [2-[[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 812697-27-1 CAPLUS
CN Carbamic acid, [(1S)-4-[(aminoiminomethyl)amino]-1-[[[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 812697-37-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[1,10-dioxo-10-[[(6-phenylimidazo[2,1-b]-

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-22-6 CAPLUS
CN Butanamide, N-[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-23-7 CAPLUS
CN Hexadecanamide, N-[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-24-8 CAPLUS
CN Carbamic acid, [[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 812697-25-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

1,3,4-thiadiazol-2-yl)sulfonyl]imino]decyl]-ω-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:491236 CAPLUS
DOCUMENT NUMBER: 139:69270
TITLE: Preparation of imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides as neuroprotective agents
INVENTOR(S): Jaquith, James B.; Villeneuve, Gerald; Boudreault, Alain; Morris, Stephen; Durkin, Jon; Gillard, John W.; Hewitt, Kimberly; Marsh, Nicholas H.
PATENT ASSIGNEE(S): Aegera Therapeutics Inc., Can.
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051890	A1	20030626	WO 2002-CA1942	20021216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2364985	A1	20030614	CA 2001-2364985	20011214
CA 2469953	A1	20030626	CA 2002-2469953	20021216
AU 2002350333	A1	20030630	AU 2002-350333	20021216
AU 2002350333	B2	20080821		
EP 1463735	A1	20041006	EP 2002-784979	20021216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005519882	T	20050707	JP 2003-552772	20021216
US 20050069492	A1	20050331	US 2004-498548	20040614
US 7230019	B2	20070612		
US 20070021476	A1	20070125	US 2006-399010	20060405
US 20070021416	A1	20070125	US 2006-398806	20060406
US 20070088059	A1	20070419	US 2006-399033	20060406
US 20070238768	A1	20071011	US 2007-797664	20070507
US 20070238766	A1	20071011	US 2007-797665	20070507
US 20070265319	A1	20071115	US 2007-797663	20070507
US 20090042953	A1	20090212	US 2008-99123	20080407

PRIORITY APPLN. INFO.:
CA 2001-2364985 A 20011214
WO 2002-CA1942 W 20021216
US 2004-498548 A3 20040614
US 2007-797665 A1 20070507

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 550366-44-4 CAPLUS
CN Carbamic acid, [[6-[4-[2-(acetyloxy)ethoxy]phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 139:69270
GI



AB This invention relates to imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides (shown as I; variables defined below; e.g. 6-phenylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide) and their use as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. For I: R1 and R2 = H, lower alkyl, substituted lower alkyl, and fluoroalkyl; R5 = H, halo, cyano, azido, thiocyanato, formyl, (un)substituted lower alkyl, fluoroalkyl, (un)substituted aralkyl, (un)substituted aryl, (un)substituted heteroaryl; R6 = H, (un)substituted lower alkyl, (un)substituted fluoroalkyl, (un)substituted aryl, (un)substituted heteroaryl, adamantly, and (un)substituted coumarinyl, etc.; addnl. details including provisos are given in the claims. Pharmacol. results are reported for some I for rescue from anti-neuronal growth factor killing of sympathetic ganglia neurons, in vitro protection of sympathetic ganglia neurons from Taxol, cisplatin and vincristine killing, protection of motor neurons in laver V of the motor cortex, cotreatment of HA460 and OV2008 cell line with Taxol and 6-phenylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide, protection of Sprague Dawley rats from Taxol-induced neuropathies, sciatic nerve crush injury model, optical stroke model, CA II inhibition, and neuroprotection of cortical neurons in the presence of B-amyloid,. Although the methods of preparation are not claimed, 153 example prepns. of I are included.
IT 550366-43-3P, N-Boc-6-[4-(2-hydroxyethoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide 550366-44-4P, N-Boc-6-[4-(2-acetoxyethoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides as neuroprotective agents)
RN 550366-43-3 CAPLUS
CN Carbamic acid, [[6-[4-(2-hydroxyethoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



```
=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    13.28     200.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.64      -1.64

STN INTERNATIONAL LOGOFF AT 19:48:12 ON 01 MAR 2009
```